Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 25, Pages 4945-4951
Publisher
American Society of Hematology
Online
2012-08-23
DOI
10.1182/blood-2012-06-434639
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
- (2011) M. A. Sekeres et al. BLOOD
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- (2011) P. Fenaux et al. BLOOD
- Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
- (2011) D A Pollyea et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
- (2010) Mikkael A. Sekeres et al. AMERICAN JOURNAL OF HEMATOLOGY
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
- (2010) T. A. Fehniger et al. BLOOD
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
- (2010) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
- (2010) William Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies
- (2009) Jaroslaw P. Maciejewski et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
- (2009) Roger M. Lyons et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
- (2009) S. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
- (2008) L. Ades et al. BLOOD
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
- (2008) Y. Jiang et al. BLOOD
- Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
- (2008) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
- (2008) Mikkael A. Sekeres et al. JNCI-Journal of the National Cancer Institute
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
- (2008) Benjamin L. Ebert et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started